P045 The relationship between thiol/disulphide and inflammatory bowel disease
H. Akinci*1, Y. Coskun1, O. Erel2, M. Hamamci1, F. Karaahmet1, S. Kilincalp1, M. Alisik2, I. Yuksel1, 3
1Diskapi Yildirim Beyazit Education and Research Hospital, Gastroenterology, Ankara, Turkey, 2Yildirim Beyazit University School of Medicine, Biochemistry, Ankara, Turkey, 3Yildirim Beyazit University School of Medicine, Gastroenterology, Ankara, Turkey
Thiol/disulphide homeostasis status has critical roles in antioxidant protection, detoxification, apoptosis, and cellular signalling mechanisms. In this study, we looked for associations between thiol/disulphide, disease presence and disease activity in patients with Crohn’s disease (CD) and ulcerative colitis (UC).
We analysed 177 patients with IBD (118 CD; 59 UC). Laboratory tests included complete blood count. Serum thiol/disulphide levels were measured with a novel automated clinical chemistry analyser (Roche, cobas 501, Mannheim, Germany). For measuring disease activation, CDAI was used in patients with CD, and the Mayo score in patients with UC. We collected data regarding patients’ clinical history, disease course, and disease clinical activity at enrolment.
Of 177 patients with IBD, 16 had active UC, 43 inactive UC, 49 active CD, and 69 inactive CD. Mean age at enrolment was 38.16 ± 12.57 years for CD (51 female / 67 male) and 39.33 ± 13.86 years for UC (25 female / 34 male). Of the CD patients, 39 had ileal, 6 colonic, and 73 ileocolonic diseases. Of the UC patients, 13 had proctitis, 23 left-sided colitis, and 23 extensive colitis. A control group of 30 patients was included the study (16 female / 14 male, mean age 36.13 ± 15.11).
Native thiol levels were significantly higher in the overall group of patients with CD (427.85 ± 75.06 µmol/L, p = 0.04) and in the overall group of patients with UC (431.01 ± 75.62 µmol/L, p = 0.02) compared with the control group (407.25 ± 48.69 µmol/L). On the other side of homeostasis, disulphide was lower in patients with CD (19.77 ± 6.50 µmol/L, p = 0.01) compared with controls (23.87 ± 7.96 µmol/L). Native and total thiol levels (442.50 ± 70.03, p = 0.01 and 480.65 ± 68.18 µmol/L, p = 0.02) were significantly higher in patients with inactive CD than in patients with active CD (407.20 ± 77.72 and 448.67 ± 78.60 µmol/L). There were no thiol / disulphide differences between patients with active UC and inactive UC, and between patients with CD and patients with UC. There was no statistical association between thiol / disulphide levels and disease extension in UC, or disease localisation and behaviour in CD.
Levels of native thiol in patients with CD and UC were higher than in control subjects. Thiol levels in patients with inactive CD were higher than in patients with active CD. Decreased levels of thiol in patients with active CD and active UC suggest increased oxidation. Further research is necessary to investigate the functional properties of thiol/disulphide homeostasis in IBD, which could provide opportunities for evaluation of response to therapy and novel insights into pathophysiology and therapy.